AMO959 + Enzalutamide + Abiraterone
Phase 1/2RecruitingDevelopment Stage
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Dec 5, 2025 → Sep 13, 2029
About AMO959 + Enzalutamide + Abiraterone
AMO959 + Enzalutamide + Abiraterone is a phase 1/2 stage product being developed by Novartis for PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07226986. Target conditions include PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07226986 | Phase 1/2 | Recruiting |
Competing Products
1 competing product in PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-4357 injection + Enzalutamide；Abiraterone | Jiangsu Hengrui Medicine | Phase 3 | 77 |